1. |
β-Blockers for the prevention of perioperative cardiac events |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Pharmacists to be key players in pharmacogenomics? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Salmeterol/fluticasone propionate cost effective in asthma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 5-6
Raewyn Poole,
Preview
|
|
摘要:
Asthma is a chronic respiratory illness that is common in developed countries. It has a significant impact in terms of treatment costs and its effect on quality of life. The combination of salmeterol/fluticasone propionate ['Seretide'; 'Advair'] is more cost effective than montelukast ['Singulair'] in the first-line treatment of asthma in adults, according to a presentation at the 58th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [New York, US; March 2002].1Researchers analysed results from two multicentre studies comparing the two products and concluded that, although costs were slightly higher for salmeterol/fluticasone propionate, compared with montelukast, this was offset by its greater efficacy. In another study presented at the meeting, the combination of salmeterol/fluticasone propionate was shown to provide greater improvement in quality of life (QOL) than either of its individual components alone.2
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Rivastigmine often underdosed in Alzheimer's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
'Room for improvement'in unstable angina, NSTEMI |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Dutasteride: rapid benefit in patients with BPH |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 9-10
Raewyn Poole,
Preview
|
|
摘要:
Dutasteride ['Avolve'], a 5-α reductase inhibitor, is well tolerated and effective in the treatment of benign prostatic hyperplasia (BPH), according to studies presented at the 17th Congress of the European Association of Urology (EAU) [Birmingham, UK; February 2002]. Combined 2-year results from three phase III studies demonstrated that, in addition to relieving symptoms such as acute urinary retention (AUR), dutasteride monotherapy was effective in slowing the progression of BPH. Furthermore, results from the Symptom Management After Reducing Therapy (SMART) study showed that initial combination therapy with dutasteride and the α1A-adrenoceptor antagonist, tamsulosin ['Flomax'], followed by dutasteride monotherapy not only provided rapid relief of BPH symptoms but also treated the underlying condition itself.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Antichlamydial therapy after MI improves survival |
|
Inpharma Weekly,
Volume &NA;,
Issue 1331,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|